Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

218 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.
Schnitzbauer AA, Zuelke C, Graeb C, Rochon J, Bilbao I, Burra P, de Jong KP, Duvoux C, Kneteman NM, Adam R, Bechstein WO, Becker T, Beckebaum S, Chazouillères O, Cillo U, Colledan M, Fändrich F, Gugenheim J, Hauss JP, Heise M, Hidalgo E, Jamieson N, Königsrainer A, Lamby PE, Lerut JP, Mäkisalo H, Margreiter R, Mazzaferro V, Mutzbauer I, Otto G, Pageaux GP, Pinna AD, Pirenne J, Rizell M, Rossi G, Rostaing L, Roy A, Turrion VS, Schmidt J, Troisi RI, van Hoek B, Valente U, Wolf P, Wolters H, Mirza DF, Scholz T, Steininger R, Soderdahl G, Strasser SI, Jauch KW, Neuhaus P, Schlitt HJ, Geissler EK. Schnitzbauer AA, et al. Among authors: strasser si. BMC Cancer. 2010 May 11;10:190. doi: 10.1186/1471-2407-10-190. BMC Cancer. 2010. PMID: 20459775 Free PMC article. Clinical Trial.
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
Geissler EK, Schnitzbauer AA, Zülke C, Lamby PE, Proneth A, Duvoux C, Burra P, Jauch KW, Rentsch M, Ganten TM, Schmidt J, Settmacher U, Heise M, Rossi G, Cillo U, Kneteman N, Adam R, van Hoek B, Bachellier P, Wolf P, Rostaing L, Bechstein WO, Rizell M, Powell J, Hidalgo E, Gugenheim J, Wolters H, Brockmann J, Roy A, Mutzbauer I, Schlitt A, Beckebaum S, Graeb C, Nadalin S, Valente U, Turrión VS, Jamieson N, Scholz T, Colledan M, Fändrich F, Becker T, Söderdahl G, Chazouillères O, Mäkisalo H, Pageaux GP, Steininger R, Soliman T, de Jong KP, Pirenne J, Margreiter R, Pratschke J, Pinna AD, Hauss J, Schreiber S, Strasser S, Klempnauer J, Troisi RI, Bhoori S, Lerut J, Bilbao I, Klein CG, Königsrainer A, Mirza DF, Otto G, Mazzaferro V, Neuhaus P, Schlitt HJ. Geissler EK, et al. Transplantation. 2016 Jan;100(1):116-25. doi: 10.1097/TP.0000000000000965. Transplantation. 2016. PMID: 26555945 Free PMC article. Clinical Trial.
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial.
Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau GY, Mazzaferro V, Roayaie S, Lee HC, Kokudo N, Zhang Z, Torrecilla S, Moeini A, Rodriguez-Carunchio L, Gane E, Verslype C, Croitoru AE, Cillo U, de la Mata M, Lupo L, Strasser S, Park JW, Camps J, Solé M, Thung SN, Villanueva A, Pena C, Meinhardt G, Bruix J, Llovet JM. Pinyol R, et al. Gut. 2019 Jun;68(6):1065-1075. doi: 10.1136/gutjnl-2018-316408. Epub 2018 Aug 14. Gut. 2019. PMID: 30108162 Free PMC article. Clinical Trial.
mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors.
Schnitzbauer AA, Filmann N, Adam R, Bachellier P, Bechstein WO, Becker T, Bhoori S, Bilbao I, Brockmann J, Burra P, Chazoullières O, Cillo U, Colledan M, Duvoux C, Ganten TM, Gugenheim J, Heise M, van Hoek B, Jamieson N, de Jong KP, Klein CG, Klempnauer J, Kneteman N, Lerut J, Mäkisalo H, Mazzaferro V, Mirza DF, Nadalin S, Neuhaus P, Pageaux GP, Pinna AD, Pirenne J, Pratschke J, Powel J, Rentsch M, Rizell M, Rossi G, Rostaing L, Roy A, Scholz T, Settmacher U, Soliman T, Strasser S, Söderdahl G, Troisi RI, Turrión VS, Schlitt HJ, Geissler EK. Schnitzbauer AA, et al. Ann Surg. 2020 Nov;272(5):855-862. doi: 10.1097/SLA.0000000000004280. Ann Surg. 2020. PMID: 32889867 Clinical Trial.
Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study.
Doyle A, Marsh P, Gill R, Rodov M, Mohsen W, Varma P, Hong T, Strasser SI, Bell S, Ryan M, Nicoll A, Lubel J, Gow PJ, Fink MA, Roberts S, Kemp W, Kronborg I, Arachchi N, Knight V, Dev A. Doyle A, et al. Among authors: strasser si. Scand J Gastroenterol. 2016 Aug;51(8):979-85. doi: 10.3109/00365521.2016.1166518. Epub 2016 May 10. Scand J Gastroenterol. 2016. PMID: 27161568
International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates.
Terrault NA, McCaughan GW, Curry MP, Gane E, Fagiuoli S, Fung JYY, Agarwal K, Lilly L, Strasser SI, Brown KA, Gadano A, Kwo PY, Burra P, Samuel D, Charlton M, Pessoa MG, Berenguer M. Terrault NA, et al. Among authors: strasser si. Transplantation. 2017 May;101(5):945-955. doi: 10.1097/TP.0000000000001708. Transplantation. 2017. PMID: 28437387 No abstract available.
International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients.
Terrault NA, Berenguer M, Strasser SI, Gadano A, Lilly L, Samuel D, Kwo PY, Agarwal K, Curry MP, Fagiuoli S, Fung JYY, Gane E, Brown KA, Burra P, Charlton M, Pessoa MG, McCaughan GW. Terrault NA, et al. Among authors: strasser si. Transplantation. 2017 May;101(5):956-967. doi: 10.1097/TP.0000000000001704. Transplantation. 2017. PMID: 28437388 No abstract available.
Pharmacotherapy of hepatocellular carcinoma.
Perry JF, Strasser SI, George J, Farrell GC, McCaughan GW. Perry JF, et al. Among authors: strasser si. Expert Opin Pharmacother. 2003 Dec;4(12):2175-85. doi: 10.1517/14656566.4.12.2175. Expert Opin Pharmacother. 2003. PMID: 14640916 Review.
218 results